title: t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis.
abstract: Chronic myelogenous leukemia (CML) is genetically characterized by the reciprocal translocation of chromosome 9 and 22. Around 5-8% of CML develop complex variant Ph translocations involving one or more chromosomal regions besides 9 and 22. Chromosome 3 is not frequently involved in complex translocations in CML. We report in this study a case of CML displaying a t(3;9;22) 3-way translocation. A review of the literature appears to indicate that CML patients with this translocation tend to have an aggressive course and poor outcome. Additional 3-way chromosome translocations associated with CML are also reviewed.
authors.affiliation: Department of Medicine, Mount Vernon Hospital, Mount Vernon, NY, USA.
authors.forename: Jiahuai
authors.initials: J
authors.lastname: Tan
authors.forename: Shundong
authors.initials: S
authors.lastname: Cang
authors.forename: Karen
authors.initials: K
authors.lastname: Seiter
authors.forename: Suneeta
authors.initials: S
authors.lastname: Primanneni
authors.forename: Nasir
authors.initials: N
authors.lastname: Ahmed
authors.forename: Thomas
authors.initials: T
authors.lastname: Mathews
authors.forename: Delong
authors.initials: D
authors.lastname: Liu
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001549:Benzamides; D001752:Blast Crisis / Q000235:genetics; D002892:Chromosomes, Human, Pair 22 / Q000235:genetics / Q000648:ultrastructure*; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics / Q000648:ultrastructure*; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics / Q000648:ultrastructure*; D003520:Cyclophosphamide / Q000008:administration & dosage; D000069439:Dasatinib; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D017809:Fatal Outcome; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology; D000069283:Rituximab; D013844:Thiazoles / Q000008:administration & dosage; D014178:Translocation, Genetic; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069283:Rituximab; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide; D000069439:Dasatinib; D008727:Methotrexate